Evotec Investor Day Presentation Deck
Blood glucose [mg/dl]
evotec
Random-fed blood glucose in diabetic mice implanted with GMP iPSC-derived beta cells ¹)
600-
500
400-
300-
200
100
PAGE 28
STZ
234567 10 14
Durable normalisation of blood glucose levels
iPSC-derived islet-like clusters in diabetic animal PoC study
21
H
28 35 42
49
56
63
70 77 84
Days
92
99
Animals with
control implant
Animals with
1.5 m iBeta cells
107 114 122 129 136 142146
Late pre-clinical development; Phase I expected in 2021/22
QRbeta
THERAPEUTICS
¹) Cells implanted in Theracyte non-oxygenated encapsulation devices subcutaneously in STZ-diabetic NOD-SCID mice
2) In this model, 4000 human donor islet IEQ are needed to establish normoglycemia (kidney capsule).
Assuming a B-cell content of 35%, corresponding to 1.4 M B-cells (1000 total cells per IEQ, see https://pubmed.ncbi.nlm.nih.gov/24835624/)
iPSC islet-like clusters
deliver long-lasting
normoglycemia at human
glucose setpoint²)
Significantly increased.
resistance to hypoxia and
post-implantation stress
relative to primary human
islets ³)
. GMP capabilities with
unique know-how
• Direct efficacy comparison.
to standard treatments not
feasible
3) Evotec results, in agreement with Lee et al., 2009;
https://pubmed.ncbi.nlm.nih.gov/19352116/, Shapiro et al.View entire presentation